MedTrace Logo

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. A stem cell transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Giving an infusion of the donor's T cells after the transplant may help destroy any remaining cancer cells.

PURPOSE: This phase I/II trial is studying the side effects of stem cell transplant given together with chemotherapy and biological therapy and to see how well it works in treating patients with high-risk or refractory multiple myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

CMV pp65 peptide

Given intramuscularly

BIOLOGICAL

hTERT I540/R572Y/D988Y multipeptide vaccine

Given subcutaneously

BIOLOGICAL

pneumococcal polyvalent vaccine

Given intramuscularly

BIOLOGICAL

survivin Sur1M2 peptide vaccine

Given subcutaneously

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Maryland Greenebaum Cancer Center

    lead OTHER

Principal Investigators

  • Aaron P. Rapoport, MD · University of Maryland Greenebaum Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00499577 on ClinicalTrials.gov